Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy.

Guru Sonpavde; Gregory R. Pond; Stephanie Mullane; Ana A. Ramirez; Nicholas J. Vogelzang; Andrea Necchi; Thomas Powles; Joaquim Bellmunt

doi:10.1111/bju.13674

Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy.

Guru Sonpavde, Gregory R. Pond, Stephanie Mullane, Ana A. Ramirez, Nicholas J. Vogelzang, Andrea Necchi, Thomas Powles, Joaquim Bellmunt

Fondazione IRCCS Istituto Nazionale dei Tumori

Research output: Contribution to journal › Article › peer-review

Abstract

OBJECTIVE: To study the subsequent therapy and disease outcomes of patients with advanced urothelial carcinoma (UC) after discontinuation of programmed death-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitors. PATIENTS AND METHODS: We performed a retrospective analysis to examine outcomes and systemic therapy administration after PD-1/PD-L1 inhibitor therapy in patients with advanced UC. Data on demographics and therapy administered were collected from the institutions involved in the study. Univariable Cox regression analyses were performed to examine the clinical factors potentially associated with overall survival (OS) after PD-1/PD-L1 inhibitor therapy. RESULTS: Data from 62 patients were available from four institutions, with capture of subsequent therapy and outcomes after checkpoint inhibitor immunotherapy. The median patient age was 65.5 years and 51 patients (82.3 were male. The median (range) duration of

Original language	Undefined/Unknown
Pages (from-to)	579-584
Number of pages	6
Journal	BJU International
Volume	119
Issue number	4
DOIs	https://doi.org/10.1111/bju.13674
Publication status	Published - Apr 1 2017

Keywords

outcomes, PD-1 inhibitors, PD-L1 inhibitors, post-progression therapy, Urothelial carcinoma

Access to Document

10.1111/bju.13674

Cite this

@article{b79b567d96484ac5a796a554ee06a525,

title = "Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy.",

abstract = "OBJECTIVE: To study the subsequent therapy and disease outcomes of patients with advanced urothelial carcinoma (UC) after discontinuation of programmed death-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitors. PATIENTS AND METHODS: We performed a retrospective analysis to examine outcomes and systemic therapy administration after PD-1/PD-L1 inhibitor therapy in patients with advanced UC. Data on demographics and therapy administered were collected from the institutions involved in the study. Univariable Cox regression analyses were performed to examine the clinical factors potentially associated with overall survival (OS) after PD-1/PD-L1 inhibitor therapy. RESULTS: Data from 62 patients were available from four institutions, with capture of subsequent therapy and outcomes after checkpoint inhibitor immunotherapy. The median patient age was 65.5 years and 51 patients (82.3 were male. The median (range) duration of",

keywords = "outcomes, PD-1 inhibitors, PD-L1 inhibitors, post-progression therapy, Urothelial carcinoma",

author = "Guru Sonpavde and Pond, {Gregory R.} and Stephanie Mullane and Ramirez, {Ana A.} and Vogelzang, {Nicholas J.} and Andrea Necchi and Thomas Powles and Joaquim Bellmunt",

year = "2017",

month = apr,

day = "1",

doi = "10.1111/bju.13674",

language = "Non definita",

volume = "119",

pages = "579--584",

journal = "BJU International",

issn = "1464-4096",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "4",

}

TY - JOUR

T1 - Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy.

AU - Sonpavde, Guru

AU - Pond, Gregory R.

AU - Mullane, Stephanie

AU - Ramirez, Ana A.

AU - Vogelzang, Nicholas J.

AU - Necchi, Andrea

AU - Powles, Thomas

AU - Bellmunt, Joaquim

PY - 2017/4/1

Y1 - 2017/4/1

N2 - OBJECTIVE: To study the subsequent therapy and disease outcomes of patients with advanced urothelial carcinoma (UC) after discontinuation of programmed death-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitors. PATIENTS AND METHODS: We performed a retrospective analysis to examine outcomes and systemic therapy administration after PD-1/PD-L1 inhibitor therapy in patients with advanced UC. Data on demographics and therapy administered were collected from the institutions involved in the study. Univariable Cox regression analyses were performed to examine the clinical factors potentially associated with overall survival (OS) after PD-1/PD-L1 inhibitor therapy. RESULTS: Data from 62 patients were available from four institutions, with capture of subsequent therapy and outcomes after checkpoint inhibitor immunotherapy. The median patient age was 65.5 years and 51 patients (82.3 were male. The median (range) duration of

AB - OBJECTIVE: To study the subsequent therapy and disease outcomes of patients with advanced urothelial carcinoma (UC) after discontinuation of programmed death-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitors. PATIENTS AND METHODS: We performed a retrospective analysis to examine outcomes and systemic therapy administration after PD-1/PD-L1 inhibitor therapy in patients with advanced UC. Data on demographics and therapy administered were collected from the institutions involved in the study. Univariable Cox regression analyses were performed to examine the clinical factors potentially associated with overall survival (OS) after PD-1/PD-L1 inhibitor therapy. RESULTS: Data from 62 patients were available from four institutions, with capture of subsequent therapy and outcomes after checkpoint inhibitor immunotherapy. The median patient age was 65.5 years and 51 patients (82.3 were male. The median (range) duration of

KW - outcomes, PD-1 inhibitors, PD-L1 inhibitors, post-progression therapy, Urothelial carcinoma

U2 - 10.1111/bju.13674

DO - 10.1111/bju.13674

M3 - Articolo

VL - 119

SP - 579

EP - 584

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 4

ER -